Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04460703 · ClinicalTrials.gov registry record · NA
COVID-19 Vaccine Messaging, Part 1
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 4,000
- Enrollment target
NCT04460703: Completed NA study, sponsored by Yale University.
NCT04460703 is a NA study that has completed, run by Yale University. The registered enrollment target is 4,000 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (185% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04460703, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,000 participants
- Enrollment target
Study Summary
This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming available between the 10 intervention arms to the 2 control arms. Study participants are recruited online by Lucid, which matches census based sampling in online recruitment.
Primary Outcome
This is a self reported measure, immediately after the intervention message, of the likelihood of getting a COVID-19 vaccination within 3 months and then 6 months of it becoming available. During analysis, responses among those assigned to different intervention messages will be compared to those in the control group.
Interventions
- OTHER Control message
- OTHER Baseline message
- OTHER Personal freedom message
- OTHER Economic freedom message
- OTHER Self-interest message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2020-07-08 |
| Phase | NA |
What the finished NCT04460703 record still lists
NCT04460703 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (185% higher).
The record links to 0 conditions, and to 5 interventions - of which Control message is the first listed.
NCT04460703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04460703 about?
NCT04460703 is a clinical study titled "COVID-19 Vaccine Messaging, Part 1". This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming avail...
What is the current status of trial NCT04460703?
This trial is currently completed. It is a NA study. The enrollment target is 4,000 participants. The study started on 2020-07-03. Estimated completion is 2020-07-08.
What interventions are being tested in trial NCT04460703?
The interventions under investigation include: Control message (OTHER), Baseline message (OTHER), Personal freedom message (OTHER), Economic freedom message (OTHER), Self-interest message (OTHER).
Who is sponsoring clinical trial NCT04460703?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04460703's enrollment target sits among peer trials
4,000 32nd of 2000 higher than 1,965 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI